Yahoo
NasdaqGM - Delayed Quote USD

ANI Pharmaceuticals, Inc. (ANIP)

67.41 -2.21 (-3.17%)
At close: November 6 at 4:00:01 PM EST
67.41 0.00 (0.00%)
After hours: November 6 at 4:00:46 PM EST
Trade ANIP on Coinbase
ANIP Q3 2026 earnings call
Replay the call for the latest insights.
Read transcript
Chart Range Bar
Loading chart for ANIP
  • Previous Close 69.62
  • Open 69.05
  • Bid 56.91 x 200
  • Ask 103.53 x 200
  • Day's Range 67.14 - 70.94
  • 52 Week Range 67.14 - 95.45
  • Volume 578,175
  • Avg. Volume 403,607
  • Market Cap (intraday) 1.548B
  • Beta (5Y Monthly) --
  • PE Ratio (TTM) 13.87
  • EPS (TTM) 4.86
  • Earnings Date Nov 5, 2026
  • Forward Dividend & Yield -- (0.00%)
  • 1y Target Est 105.78
  • Motley Fool Rating Bullish

ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic pharmaceutical products in the United States and internationally. The company provides injectables, softgel capsules, and Cortrophin gel, as well as ILUVIEN and YUTIQ products. It also manufactures oral solid dose products, semi-solids, liquids, topicals, controlled substances, and potent products. The company serves its products to national wholesalers, specialty pharmacies, retail pharmacy chains, distributors, mail order houses, group purchasing organizations, and hospitals and healthcare providers. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.

www.anipharmaceuticals.com

970

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Recent News

View More

Performance Overview

Trailing total returns as of 11/6/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

ANIP
14.61%
S&P 500 (^GSPC)
7.76%

1-Year Return

ANIP
25.29%
S&P 500 (^GSPC)
9.77%

3-Year Return

ANIP
7.08%
S&P 500 (^GSPC)
68.96%

5-Year Return

ANIP
34.77%
S&P 500 (^GSPC)
57.04%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q3 FY26
Revenue 290.78M
Earnings 35.15M
Profit Margin 12.09%

Q4

FY25

Q1

FY26

Q2

FY26

Q3

FY26

0
100M
200M
10.0%
11.0%
12.0%

Analyst Insights

View More

Analyst Price Targets

85.00
105.78 Average
67.41 Current
121.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 11/6/2026
Analyst Guggenheim
Rating Action Maintains
Rating Buy
Price Action Raises
Price Target 119 -> 121

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    11.22%

  • Return on Assets (ttm)

    6.77%

  • Return on Equity (ttm)

    20.45%

  • Revenue (ttm)

    1.04B

  • Net Income Avi to Common (ttm)

    114.73M

  • Diluted EPS (ttm)

    4.86

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    436.35M

  • Total Debt/Equity (mrq)

    95.31%

  • Levered Free Cash Flow (ttm)

    163.19M

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: